TimesSquare Capital Management LLC Reduces Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

TimesSquare Capital Management LLC trimmed its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 2.1% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 872,537 shares of the company’s stock after selling 18,551 shares during the period. TimesSquare Capital Management LLC’s holdings in NewAmsterdam Pharma were worth $15,802,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Quarry LP bought a new position in shares of NewAmsterdam Pharma during the first quarter valued at $25,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after buying an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of NewAmsterdam Pharma by 130.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company’s stock worth $123,000 after acquiring an additional 3,390 shares in the last quarter. Avanza Fonder AB increased its holdings in shares of NewAmsterdam Pharma by 21.0% in the 2nd quarter. Avanza Fonder AB now owns 7,505 shares of the company’s stock worth $136,000 after buying an additional 1,300 shares during the last quarter. Finally, KLP Kapitalforvaltning AS raised its stake in shares of NewAmsterdam Pharma by 51.7% in the second quarter. KLP Kapitalforvaltning AS now owns 9,100 shares of the company’s stock valued at $165,000 after acquiring an additional 3,100 shares during the period. Institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the topic of several recent analyst reports. HC Wainwright assumed coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price target on the stock. Citigroup lifted their price objective on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Royal Bank Of Canada increased their price target on NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company initiated coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They issued an “overweight” rating and a $45.00 price objective for the company. Finally, Needham & Company LLC upped their target price on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.30.

Insider Buying and Selling

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total transaction of $3,874,500.00. Following the sale, the chief accounting officer owned 15,000 shares of the company’s stock, valued at $387,450. The trade was a 90.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the sale, the insider owned 119,302 shares in the company, valued at approximately $2,897,845.58. This trade represents a 29.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 226,342 shares of company stock worth $5,748,019 in the last ninety days. Insiders own 20.84% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $38.26 on Thursday. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $41.47. The stock has a 50 day moving average of $32.30 and a 200 day moving average of $24.91. The firm has a market capitalization of $4.31 billion, a price-to-earnings ratio of -18.66 and a beta of 0.05.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. Analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.